SHILPAMED vs WOCKPHARMA: Stock Comparison

Shilpa Medicare Limited vs Wockhardt Ltd

Live data: 22 July 2026, 3:05 PM IST • Source: NSE and company filings

Wockhardt Ltd is the larger company by market capitalisation. Shilpa Medicare Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Shilpa Medicare Limited and Wockhardt Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, SHILPAMED is more favourable on 11 of 13 scored metrics and WOCKPHARMA on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,362 Cr vs ₹12,013 Cr
P/E Ratio
SHILPAMED has a lower P/E
51.29x vs 144.46x
P/B Ratio
SHILPAMED has a lower P/B
4.82x vs 6.23x
EPS
WOCKPHARMA has higher earnings per share
₹13.1 vs ₹12.44
Dividend Yield
SHILPAMED has a higher dividend yield
0.08% vs 0%
Revenue Growth (TTM YoY)
SHILPAMED has faster revenue growth
31.5% vs 26%
EPS Growth (TTM YoY)
SHILPAMED has faster EPS growth
644.6% vs 0%
Qtr Sales Growth
SHILPAMED has stronger quarterly sales growth
32.1% vs 29.9%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricSHILPAMEDWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricSHILPAMEDWOCKPHARMA
Live Price₹614.3₹1,865
Day Change-4.02%-1.65%
Volume4.88 L7.27 L
52-Week High₹860₹2,422.3
52-Week Low₹259.5₹1,086.7
Distance from 52W High-28.57%-23.01%

Valuation

MetricSHILPAMEDWOCKPHARMA
Market Cap₹12,013 Cr₹30,362 Cr
P/E Ratio51.29x144.46x
P/B Ratio4.82x6.23x
EPS₹12.44₹13.1
Book Value₹132.46₹304
Dividend Yield0.08%0%

Growth

MetricSHILPAMEDWOCKPHARMA
Revenue Growth (TTM YoY)31.5%26%
EPS Growth (TTM YoY)644.6%0%
Qtr Sales Growth32.1%29.9%
Qtr Profit Growth148%688%

Profitability & Leverage

MetricSHILPAMEDWOCKPHARMA
ROE9.4%6.11%
ROCE11%7.55%
Net Margin15.82%3.3%
Operating Margin28.2%19.3%
Debt to Equity0.25x0.45x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricSHILPAMEDWOCKPHARMA
Promoter Holding40.13%49.08%
FII Holding11.38% 0.3 pp7.09% 0.1 pp
DII Holding8.05% 0.53 pp10.96% 0.41 pp
Public Holding40.43% 0.22 pp32.83% 0.52 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Shilpa Medicare Limited and Wockhardt Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.